How to Buy Suboxone (Buprenorphine/Naloxone) Online

What Is Suboxone?

Suboxone is a combination medication containing buprenorphine (a partial mu-opioid agonist) and naloxone (an opioid antagonist). It is the most commonly prescribed medication for the treatment of opioid use disorder (OUD) in the United States.

The combination of buprenorphine and naloxone is designed to deter misuse. When taken as directed (sublingually or buccally), the naloxone has minimal effect. However, if the medication is injected intravenously, the naloxone becomes active and can precipitate severe withdrawal.

Suboxone is designated as a Schedule III controlled substance under the federal Controlled Substances Act. In December 2022, the federal X-waiver requirement was eliminated, allowing all DEA-registered practitioners to prescribe buprenorphine for OUD.

How Suboxone Works

Buprenorphine is a partial mu-opioid agonist. Unlike full opioid agonists (such as heroin, oxycodone, or fentanyl), buprenorphine only partially activates mu-opioid receptors. This means it produces enough opioid effect to:

• Reduce withdrawal symptoms — alleviates the discomfort of opioid withdrawal
• Decrease cravings — reduces the intense desire to use opioids
• Block other opioids — because buprenorphine has a high receptor binding affinity, it "occupies" mu receptors and prevents other opioids from binding

Buprenorphine has a ceiling effect — beyond a certain dose, increasing the dose does not produce additional opioid effects. This ceiling effect reduces the risk of respiratory depression compared to full agonists.

Naloxone is an opioid antagonist that blocks mu receptors. In the Suboxone formulation, naloxone serves as a deterrent to misuse. When the film or tablet is taken sublingually as directed, naloxone has poor bioavailability and has minimal effect. If injected, naloxone becomes fully active and can precipitate acute withdrawal.

FDA Schedule & Classification

FDA-Approved Uses

Suboxone is FDA-approved for the induction and maintenance treatment of opioid dependence (opioid use disorder).

• Induction: Starting Suboxone during opioid withdrawal to transition from full opioid agonists
• Maintenance: Ongoing treatment to sustain recovery, reduce cravings, and prevent relapse
• Detoxification: Gradually tapering to discontinue opioid use under medical supervision

Suboxone should be used as part of a comprehensive treatment program that includes counseling and behavioral therapy. Medication-assisted treatment (MAT) with buprenorphine is considered the gold standard for opioid use disorder.

Dosage Forms & Strengths

Sublingual Film (Suboxone)

Sublingual Tablet (Generic)

The typical induction dose is started after the patient is in moderate opioid withdrawal (typically 12—24 hours after short-acting opioids, 24—72 hours after long-acting opioids). The target maintenance dose is typically 8 to 16 mg per day, with a maximum of 24 mg per day.

Side Effects

Common Side Effects

• Headache
• Nausea and vomiting
• Constipation
• Pain (general)
• Sweating
• Insomnia
• Mouth numbness or pain (from sublingual administration)
• Tongue pain
• Dizziness

Serious Side Effects

Contact your healthcare provider or seek emergency medical attention if you experience:

• Respiratory depression — especially if combined with benzodiazepines, alcohol, or other CNS depressants
• Severe allergic reaction (anaphylaxis)
• Adrenal insufficiency
• Hepatotoxicity — jaundice, dark urine, right upper abdominal pain
• QT prolongation (rare)
• Neonatal withdrawal — if used during pregnancy, the infant may require monitoring and treatment for opioid withdrawal

Drug Interactions

Major Interactions (Avoid or Use Extreme Caution)

• Benzodiazepines — concurrent use can cause profound sedation, respiratory depression, coma, and death; this is the most common cause of death in buprenorphine-treated patients
• Alcohol — additive CNS depression
• Other opioids — risk of respiratory depression; can also precipitate withdrawal if buprenorphine is added
• MAO inhibitors — potentially dangerous interaction
• CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin) — may increase buprenorphine levels

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (rifampin, carbamazepine, phenytoin) — may decrease buprenorphine effectiveness
• Benzodiazepine-like drugs (buspirone, gabapentin) — may increase sedation
• Serotonergic drugs — theoretical risk of serotonin syndrome

Precautions & Warnings

• Precipitated Withdrawal: Must be in moderate opioid withdrawal before starting Suboxone to avoid precipitated withdrawal.
• Pregnancy: Buprenorphine is recommended for opioid use disorder during pregnancy. Suboxone (with naloxone) is generally not recommended during pregnancy due to limited safety data; many providers use buprenorphine alone (Subutex) during pregnancy.
• Breastfeeding: Generally considered compatible with breastfeeding. Buprenorphine is excreted in small amounts in breast milk.
• Liver disease: Use with caution in patients with hepatic impairment. Monitor liver function regularly.
• History of substance use disorder: Suboxone is prescribed specifically for this condition, but misuse is possible (e.g., injecting the film).
• Adrenal insufficiency: Opioids, including buprenorphine, can cause adrenal insufficiency. Monitor for symptoms.
• Driving and machinery: May cause drowsiness, especially during induction.
• Emergency situations: Inform all healthcare providers that you are taking Suboxone. The opioid-reversal dose of naloxone may need to be higher.

When to Contact a Clinician

• You are still experiencing cravings or withdrawal symptoms after starting treatment
• You notice new or unexpected side effects
• You are having difficulty functioning at work or home
• You are experiencing mood changes, depression, or thoughts of self-harm
• You are pregnant or planning to become pregnant
• You are thinking about stopping treatment — talk to your provider first
• You have been started on a new medication by another provider

Seek emergency care immediately if you experience difficulty breathing, severe allergic reaction, loss of consciousness, or symptoms of overdose (even though buprenorphine has a ceiling effect, overdose can still occur, especially when combined with other CNS depressants).